HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Galiximab: a review.

AbstractIMPORTANCE OF THE FIELD:
A significant number of patients relapse or do not respond to rituximab due to intrinsic or acquired resistance. Hence, mAbs targeting other cell surface antigens on B-cell lymphomas are being studied. CD80 is a glycoprotein expressed on Hodgkin's lymphoma, mature B-cell lymphomas and immunoeffector cells which may have T-regulatory, in addition to direct antitumor activity. CD80 serves as an attractive target in the continued development of mAbs against lymphoma.
AREAS COVERED IN THIS REVIEW:
Preclinical studies with galiximab, an anti-CD80 primatized mAb, have been encouraging and have demonstrated antitumor activity against various B-cell lymphoma models, both as a single agent as well as in combination with rituximab. Data were reviewed from a PubMed literature search from 1975 to 2009 and also included a review of abstracts from published proceedings of annual meetings from the American Society of Hematology and International Conference of Malignant Lymphoma, Lugano.
WHAT THE READER WILL GAIN:
Readers will gain a better understanding of mechanisms of action (both documented and proposed) of galiximab. An update of currently available clinical data will be presented.
TAKE HOME MESSAGE:
Data from completed clinical trials are promising and galiximab is being studied in both upfront and relapsed settings with the potential of being incorporated into the future treatment of B-cell lymphoma.
AuthorsSeema Bhat, Myron S Czuczman
JournalExpert opinion on biological therapy (Expert Opin Biol Ther) Vol. 10 Issue 3 Pg. 451-8 (Mar 2010) ISSN: 1744-7682 [Electronic] England
PMID20092425 (Publication Type: Journal Article, Review)
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • B7-1 Antigen
  • galiximab
Topics
  • Antibodies, Monoclonal (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • B7-1 Antigen (immunology)
  • Humans
  • Lymphoma, Non-Hodgkin (drug therapy, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: